Navigation Links
Expert insights on in vitro alternatives for drug and chemical toxicity testing
Date:8/7/2014

New Rochelle, NY, August 7, 2014In vitro toxicity testing is rapidly being adopted in the pharmaceutical, chemical, and cosmetics industries, for example, as an alternative to animal studies to predict adverse health effects of drugs and personal care products and the health consequences of environmental exposures. An insightful Roundtable Discussion focused on how to apply these novel toxicology models to everyday hazard prediction, risk assessment, and decision making in industry is published in the preview issue of the new journal Applied In Vitro Toxicology, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article is available free on the Applied In Vitro Toxicology website.

In the Roundtable Discussion "Comments on How to Make the New Vision of Toxicity Testing in the 21st Century a Reality," Moderator Jim McKim, Editor-in-Chief of Applied In Vitro Toxicology and Founder and CEO, IONTOX, LLC, challenges the panelists to present a realistic view of how far the field has advanced in implementing the strategy put forth in a National Academy of Sciences report to improve toxicity testing.

Panelists Alan Goldberg, Consulting Editor of the Journal, Nicole Kleinstreuer, ILS/National Toxicology Program Interagency Center for Evaluation of Alternative Toxicological Methods (Research Triangle Park, NC), Francois Busquet, Center for Alternatives to Animal Testing (Konstanz, Germany), and Melvin Andersen, The Hamner Institutes for Health Sciences (RTP, NC) participate in an interactive discussion on the use of human cell models combined with high-throughput screening methods to test for toxicity, and the complexity of applying adverse outcome pathways (AOPs). The conversation covers topics ranging from policy issues, challenges related to data interpretation and understanding the information gained from in vitro models, the emergence of three-dimensional tissue culture models that integrate cells from multiple human organs, and the different approaches being used to assess risk from high-dose, short-term exposures compared to exposure to lower concentrations of a chemical over longer periods of time.

"Improved analytical technologies and improvements in human tissue models will allow us to change the animal safety testing paradigm," says Jim McKim.


'/>"/>

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Related biology news :

1. Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT
2. Experts voice concerns over arsenic in rice, reports Journal of Pediatric Gastroenterology and Nutrition
3. Top aging research experts to present at 43rd Annual American Aging Association Conference
4. Solar energy prospects are bright for Scotland, experts say
5. CHOP expert Dr. Garrett Brodeur honored for career work in neuroblastoma
6. MIPT experts reveal the secret of radiation vulnerability
7. Control methane now, greenhouse gas expert warns
8. Wildlife response to climate change is likely underestimated, experts warn
9. International research group recognizes UTMB experts
10. Experts disagree on horses with incoordination
11. The metrology experts of the future come from Braunschweig
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Expert insights on in vitro alternatives for drug and chemical toxicity testing
(Date:3/2/2017)... 2, 2017 Summary This report ... Merck KGaA and its partnering interests and activities since ... Description The Partnering Deals and Alliance since 2010 ... of one of the world,s leading life sciences companies. ... purchase to ensure inclusion of the most up to ...
(Date:3/2/2017)... 2017 Australian stem cell and regenerative medicine ... signed an agreement with the Monash Lung Biology Network, ... Institute and Department of Pharmacology at Monash University, ... study to support the use of Cymerus™ mesenchymal stem ... Asthma is a chronic, long term lung condition ...
(Date:2/28/2017)... 2017   Acuant , a leading provider of ... enhancements to new and core technologies building upon the ... mobile and desktop Acuant FRM TM facial recognition ... real time manual review of identity documents by accredited ... fastest and most accurate capture software to streamline workflows ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... NEW YORK , March 23, 2017 ... closer look at four equities in the Biotech industry: ... EYEG), Synthetic Biologics Inc. (NYSE MKT: SYN), and Regulus ... March 21 st , 2017, Credit Suisse upgraded its rating ... stocks by downloading their free report at: ...
(Date:3/22/2017)... 22, 2017  UBM and the Massachusetts Medical ... extended partnership and the third annual Massachusetts Medtech Week. ... 21 st Annual MassMEDIC Conference held in ... 3-4, 2017. MassMEDIC will feature ... President and CEO, Scott Whitaker , at ...
(Date:3/22/2017)... March 22, 2017 MarketNewsUpdates.com News Commentary  ... The ... are being pressured as of late due to the rise ... management has a dramatic impact on patient,s quality of life ... activities for identifying new forms of opioid formulations that prevent ...
(Date:3/22/2017)... ... March 21, 2017 , ... Okyanos Cell Therapy has announced Tallahassee, FL will ... events series, “Stem Cell Therapy: The Next Phase in the Evolution of Medicine.” As ... Cell Research and Therapy Act, Okyanos maintains a mission to help “no-option” patients ...
Breaking Biology Technology: